Source comparison
VIP Thymosin Alpha-1 Protocol CIRS Research: Comparison
VIP Intranasal Monotherapy Restores hypothalamic-pituitary regulation; upregulates MSH, VEGF, leptin MSH >35 pg/mL, MMP-9 <332 ng/mL, VCS improvement 2–4 weeks for VCS, 6–8 weeks for MSH normalisation Does not address T-regulatory cell depletion; limited effec
This comparison does not assign a generated winner or score.
- VIP Intranasal Monotherapy
- Restores hypothalamic-pituitary regulation; upregulates MSH, VEGF, leptin
- MSH >35 pg/mL, MMP-9 <332 ng/mL, VCS improvement
- 2–4 weeks for VCS, 6–8 weeks for MSH normalisation
- Does not address T-regulatory cell depletion; limited effect on exercise intolerance and PEM
- Best as first-line therapy for patients with predominant autonomic symptoms (POTS, temperature dysregulation). Inadequate as monotherapy for full CIRS resolution.
- Thymosin Alpha-1 Monotherapy
- Activates TLR-2/TLR-9 pathways; restores CD4+CD25+ T-regulatory cells and IL-2 production
- CD4+CD25+ >7%, IL-2 elevation, reduced autoimmune markers
- 8–12 weeks for T-reg restoration, 10–14 weeks for functional improvement
- Does not restore MSH or address hypothalamic dysfunction; VCS deficits may persist
- Appropriate for patients with confirmed T-cell exhaustion and autoimmune cross-reactivity. Insufficient for patients with persistent VCS deficits or low MSH.
- VIP + Thymosin Alpha-1 Dual Protocol
- Simultaneous autonomic and adaptive immune restoration; addresses both hypothalamic and T-cell pathways
- MSH, MMP-9, VCS, CD4+CD25+, IL-2, TGF-beta-1
- VIP effects 2–4 weeks; TA1 effects 8–12 weeks; full resolution 16–24 weeks
- Requires staged initiation to avoid Herxheimer reactions; higher cost; nasal VIP contraindicated in active sinus infection
- Gold standard for patients meeting full Shoemaker CIRS criteria. Addresses both autonomic dysregulation and immune collapse simultaneously. Single-agent therapy leaves one pathway untreated.